04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
19:19 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; colorectal cancer; pancreatic cancer In vitro and cell culture studies identified a hydrazone-based inhibitor of RRM1 that could help treat breast, colorectal and pancreatic cancers. In silico screening of a small molecule...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

COH29: Phase I started

City of Hope and Novonco began an open-label, dose-escalation, U.S. Phase I trial to evaluate oral COH29 twice daily on days 1-21 of each 28-day cycle in about 27 patients. Last year, City of Hope...
07:00 , Mar 21, 2016 |  BioCentury  |  Emerging Company Profile

Targeting toxicity

Novonco Therapeutics Inc. is developing a pipeline of targeted cancer therapies that were designed at City of Hope and University of California Irvine to be less toxic than either first-generation inhibitors, or parent molecules. Its...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

City of Hope, Novonco Therapeutics deal

City of Hope granted Novonco exclusive rights to COH29 . The small molecule ribonucleotide reductase inhibitor is in preclinical testing to treat cancer. Novonco plans to start U.S. clinical trials this year. Novonco did not...
07:00 , Jul 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ribonucleotide reductase M1 (RRM1; R1); ribonucleotide reductase M2 (RRM2; R2)

Cardiovascular disease INDICATION: Heart failure Pig studies suggest RRM1 and RRM2 gene therapy could help treat heart failure. In a minipig model of heart failure, intracoronary infusion of an adeno-associated virus (AAV) serotype 6 (AAV6)...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ribonucleotide reductase M1 (RRM1; R1); ribonucleotide reductase M2 (RRM2; R2)

Cardiovascular disease INDICATION: Heart failure Studies in human samples suggest 2-deoxy ATP (dATP) could help treat heart failure. In de-membranated multicellular preparations of ventricular wall tissue from patients with end-stage heart failure, treatment with dATP...
08:00 , Feb 19, 2015 |  BC Innovations  |  Targets & Mechanisms

Ace of hearts

Less than two years after coming out of stealth mode, University of Washington spinout Beat BioTherapeutics Corp. has shown preclinical proof of concept for its heart failure gene therapy designed to provide dATP as an...
14:51 , Feb 13, 2015 |  BC Innovations  |  Targets & Mechanisms

Ace of hearts

Less than two years after coming out of stealth mode, University of Washington spinout Beat BioTherapeutics Corp. has shown preclinical proof of concept for its heart failure gene therapy designed to provide dATP as an...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....